Immunome, Inc. (IMNM)
18.71
+0.80
(+4.50%)
USD |
NASDAQ |
Nov 06, 16:00
19.49
+0.78
(+4.17%)
After-Hours: 20:00
Immunome Cash from Investing (Quarterly) : -304.35M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -304.35M |
| March 31, 2026 | -12.02M |
| December 31, 2025 | -3.999M |
| September 30, 2025 | 123.88M |
| June 30, 2025 | -64.17M |
| March 31, 2025 | 5.089M |
| December 31, 2024 | 9.758M |
| September 30, 2024 | 24.10M |
| June 30, 2024 | -81.69M |
| March 31, 2024 | -37.23M |
| December 31, 2023 | -30.00M |
| September 30, 2023 | -0.036M |
| June 30, 2023 | -0.34M |
| Date | Value |
|---|---|
| March 31, 2023 | -0.106M |
| December 31, 2022 | -0.072M |
| September 30, 2022 | 0.00 |
| June 30, 2022 | -0.17M |
| March 31, 2022 | -0.006M |
| December 31, 2021 | -0.014M |
| September 30, 2021 | -0.026M |
| June 30, 2021 | -0.008M |
| March 31, 2021 | -0.031M |
| December 31, 2020 | -0.046M |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | -0.055M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 43.68M |
| Revolution Medicines, Inc. | 80.10M |
| Erasca, Inc. | 19.49M |
| Oncolytics Biotech, Inc. | 0.00 |
| Sangamo Therapeutics, Inc. | -0.013M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -61.69M |
| Cash from Financing (Quarterly) | 1.058M |
| Free Cash Flow | -219.09M |
| Free Cash Flow Per Share (Quarterly) | -0.5638 |
| Free Cash Flow to Equity (Quarterly) | -64.91M |
| Free Cash Flow to Firm (Quarterly) | -63.87M |
| Free Cash Flow Yield | -11.50% |